Elk River Wealth Management LLC Decreases Stock Position in Zoetis Inc. $ZTS

Elk River Wealth Management LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 40.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,183 shares of the company’s stock after selling 11,486 shares during the quarter. Elk River Wealth Management LLC’s holdings in Zoetis were worth $2,157,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 11,650 shares of company stock worth $886,384 over the last ninety days. 0.22% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of ZTS opened at $79.64 on Thursday. The business’s fifty day moving average price is $109.69 and its 200 day moving average price is $119.37. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $172.23. The stock has a market capitalization of $33.39 billion, a PE ratio of 13.21, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the business earned $1.48 earnings per share. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Morgan Stanley reiterated an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $134.75.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.